There's no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment.
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer currently has a 7% yield, and the company is making important business moves. Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions.
Anti-obesity drugs are being considered for a range of addictive behaviors. Pfizer just acquired a next-generation, clinical-stage maker of obesity treatments.

Should You Buy Pfizer Stock Before Nov. 4?

12:15pm, Monday, 27'th Oct 2025
Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock.
Kenvue was spun off from Johnson & Johnson in mid-2023, and its life is starting out a little rough. Pfizer is working through typical drug industry issues, but there's a notable dividend risk to cons
Boomers today are between 60 and 79 years old.
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Kenvue owns Johnson & Johnson's former over-the-counter brands. Medtronic has a diversified medical-device portfolio and is closing in on "Dividend King" status.
Eli Lilly and Company, Wellgistics Health, Pfizer, AbbVie, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks a
One is a pharmaceutical industry powerhouse that has fallen out of favor with investors. The other is a top REIT that cranks out a dividend far more often than the usual U.S. business.
Pfizer faces significant revenue headwinds from patent expiries, COVID product declines, and generic competition, but these risks are largely priced in. PFE's valuation is historically low at ~8x earn
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Nine of fifteen Barron's Better Bets (BBB) 'safer' high-yield dividend stocks are currently attractively priced, including CAG, VZ, MO, BMY, TFC, UDR, KEY, KIM, and RF. Analyst forecasts project top-t
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE